Mutai et al. analyzed data from 608 patients with HR-positive early breast cancer, and found that HER2-low breast cancer was associated with significant improvement in OS and DFS compared with HER-IHC 0 breast cancer in patients with high genomic risk [22]. This evidence concerns the gene ERBB2 and breast cancer.